As the world is eager to return to a normal life after living in a pandemic for more than a year, countries are scrambling to provide vaccines to slow (and hope to stop) the spread of this flu. coronavirus.

The success of this will depend on a number of factors, including the manufacture and transportation of billions of doses of drugs, to ensure Rich countries do not monopolize The worldwide supply of vaccines, and crucially, has actually given people the dose.

The chart below will be updated to show the latest data on the largest vaccination campaign in the history of the United States and the world.

we

The rate of vaccination in each state varies significantly from state to state.

The first two vaccines Officially recognized in order to Emergency use In the United States, developed by the company Pfizer/BioNTech with ModernIt is designed to be taken twice every few weeks.This Johnson The vaccine authorized in late February requires only one dose. Therefore, vaccination for every person in the United States will ultimately mean 100 to 200 doses of vaccine for every 100 people in every state and region-a total of between 330 million and 660 million doses in the country.it is Huge logistics challenge.

The introduction of vaccines in the United States has been slower than expected.The Trump administration has set a goal 20 million vaccines By the end of 2020. This goal was not achieved until late January. In early March, President Joe Biden stated that the United States will provide enough vaccines for all adults By the end of may -Two months earlier than the previous plan of his government.Despite this, there are still concerns that the vaccination situation will get worse people with Color community behind.

Search or browse in this table to understand your state or territory’s performance in these key vaccine deployment measures.

Vaccine rollout schedule

This chart shows the number of vaccines administered per 100 people in each state since the beginning of 2021. The country codes of the first three states and the U.S. are highlighted. Enter the name of any other state or U.S. territory in the search bar and select Add to chart.

The chart shows the number of people vaccinated nationwide starting from the beginning of 2021. Due to the lag in the report leading to a surge in data, the line showing the 7-day rolling average of the dose provides a clearer picture of whether the deployment is accelerating or slowing down.

world

Vaccination status in various countries

More countries appear on the map, showing the dose of vaccine given per 100 people, because these numbers are more widely reported.

In terms of vaccine launches, the United States is ahead of most other countries.But among the major countries, Israel has always been Early leader.

Search or browse the table to see the situation in each country. It reveals that some countries have adopted different strategies: for example, the United Kingdom decided to give as many people as possible the initial dose to delay the second injection.

Vaccine rollout schedule

This chart shows the number of vaccines administered per 100 people in each country/region since the beginning of 2021. Enter the name of any country/region in the search bar and choose to compare its timeline with the top three countries/regions of the United States and other leading global vaccine deployments. Only countries that have started vaccinations will appear.

The graph shows the vaccine doses reported daily to people around the world. Due to the spikes caused by the reporting delay, the line showing the 7-day rolling average for a given dose can provide a clearer picture of whether the rollout speed is accelerating or slowing.

The state of leading vaccines

The following table records the status of the leading COVID-19 vaccines, shows the authorizations for use in the United States and other light markets, and the prices in the purchase agreement information UNICEF compilation(If there is).

Pfizer/BioNTech and Moderna’s vaccines, clinical trial results show that they are more than 90% effective In the prevention of diseases, based on new technology It is possible to provide the RNA sequence that causes our own cells to produce viral proteins, thereby triggering an immune response.

The disadvantage is that these vaccines are more expensive than vaccines made by splicing the genetic material of the coronavirus into a banned version of another virus (such as those produced by the Anglo-Swedish company AstraZeneca). Based on Oxford University research, JohnsonAnd Russian Gamaria Institute.

Other leading vaccines are based on inactivated versions of the coronavirus, a long-term method of producing vaccines or protein subunits made from viruses.

Jeremy Singer-Vine provided coverage for this story.